Labomar SpA
MIL:LBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Labomar SpA
Cash & Cash Equivalents
Labomar SpA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Labomar SpA
MIL:LBM
|
Cash & Cash Equivalents
€21.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intercos SpA
MIL:ICOS
|
Cash & Cash Equivalents
€152.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Pharmanutra SpA
MIL:PHN
|
Cash & Cash Equivalents
€18.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Enervit SpA
MIL:ENV
|
Cash & Cash Equivalents
€11.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Labomar SpA
Glance View
Labomar SpA operates as a contract development manufacturing organization which specializes in the research, development, and production of food supplements, medical equipment, food for special medical purposes, and cosmetics on behalf of third parties. The company is headquartered in Treviso, Treviso and currently employs 342 full-time employees. The company went IPO on 2020-10-05. is an Italy-based company, which produces dietary supplements, in either solid format or as liquids. The firm's oral solid products include chewable tablets, swallable tablets, coated tablets, gastro-resistant tablets, time release tablets, micro tablets, hard plant or animal gelatine capsules, oro dispersible powders, and water dispersible powders. Its oral liquid products include syrups, hydroglyceric and hydroalcoholic suspensions, solutions, emulsions, and nanoemulsions. The firm serves companies operating in the medical information sector, in distribution channels in chemist and herbalists shops, retail stores of products for athletes and retail organization.
See Also
What is Labomar SpA's Cash & Cash Equivalents?
Cash & Cash Equivalents
21.1m
EUR
Based on the financial report for Dec 31, 2022, Labomar SpA's Cash & Cash Equivalents amounts to 21.1m EUR.
What is Labomar SpA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
45%
Over the last year, the Cash & Cash Equivalents growth was 49%. The average annual Cash & Cash Equivalents growth rates for Labomar SpA have been 45% over the past three years .
